Clinical Data Lilly debuts more Foundayo data as FDA requests post-marketing trials pharminent April 16, 2026
Clinical Data Lilly’s Foundayo posts ‘outstanding’ diabetes data, possibly easing FDA safety concerns pharminent April 16, 2026
M&A / Deals Obesity’s explosive growth continues as Q1 deals exceed total 2025 value pharminent April 16, 2026
Regulatory Lilly’s new obesity pill linked to ‘serious’ safety signals, FDA requests more data pharminent April 15, 2026
Manufacturing Lilly investing billions to prepare for overseas oral GLP-1 launches pharminent April 14, 2026
Other 220: An Interview With Dr. Jaime Moore on Obesity Medications and Neuromuscular Disease pharminent April 13, 2026
Commercial With oral obesity race underway, all eyes are on Lilly’s Foundayo launch pharminent April 10, 2026
M&A / Deals Gan & Lee and JW Pharmaceutical agree on bofanglutide commercialisation pharminent April 10, 2026
Commercial Lilly launches GLP-1 pill, kicking off showdown with Novo Nordisk pharminent April 9, 2026
Commercial Approvals in Hand, Lilly and Novo Obesity Pills Will Battle It Out on Hairline Differences pharminent April 2, 2026
Clinical Data ACC 2026: Meta-analysis supports CagriSema as superior first-line therapy in obesity pharminent April 2, 2026
Regulatory Eli Lilly wins FDA approval for weight loss pill, tees up Novo rivalry pharminent April 2, 2026
M&A / Deals Biocytogen and Sihuan partner to advance new therapeutics for weight loss pharminent April 2, 2026
Regulatory FDA approves Lilly obesity pill, triggering battle with Novo Nordisk pharminent April 1, 2026
Regulatory Eli Lilly’s Oral Obesity Pill Approved, Kicking Off Renewed Novo Rivalry pharminent April 1, 2026
M&A / Deals Ambrosia Eyes Next-Generation Small Molecule GLP-1s With $100M Series B pharminent April 1, 2026
Clinical Data Wave crashes on obesity drug update; Kodiak’s reboot pays dividends pharminent March 26, 2026
